On the treatment of diabetes mellitus with glucagon-like peptide-1

Ann N Y Acad Sci. 1998 Dec 11:865:336-43. doi: 10.1111/j.1749-6632.1998.tb11193.x.

Abstract

As a therapeutic principle, the insulinotropic peptide, GLP-1, of the secretin-glucagon family of peptides, has turned out to possess some remarkably attractive properties, including the capability of normalizing blood glucose concentrations in patients with non-insulin-dependent diabetes mellitus and promoting satiety and reducing food intake in healthy volunteers. Because of rapid and extensive metabolization, the peptide is not immediately clinically applicable and, as a therapeutic principle, GLP-1 is still in its infancy. Some possible avenues for circumventing these difficulties are the development of DPP-IV-resistant analogs, the inhibition of DPP-IV, enhancement of GLP-1 secretion, GLP delivery systems using continuous subcutaneous infusion or buccal tablets, GLP-1 absorption, and orally active, stable analogs. It seems likely that one or more of these approaches could result in a clinically useful development program.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Animals
  • Appetite Depressants*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Dipeptidyl Peptidase 4 / metabolism
  • Glucagon / administration & dosage
  • Glucagon / therapeutic use*
  • Glucagon-Like Peptide 1
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / therapeutic use*
  • Protein Precursors / administration & dosage
  • Protein Precursors / therapeutic use*

Substances

  • Appetite Depressants
  • Hypoglycemic Agents
  • Peptide Fragments
  • Protein Precursors
  • Glucagon-Like Peptide 1
  • Glucagon
  • Dipeptidyl Peptidase 4